While the general population regained a certain level of normalcy with the end of the global
health emergency, the risk of contracting COVID-19 with a severe outcome is still a major …

Here we describe the case of a 51 years old Italian woman with acute lymphoblastic
leukemia who underwent to hematopoietic stem cell transplantation (HSCT) during SARS …

This systematic review and meta-analysis aimed to compare the immunogenicity and safety
of an additional heterologous (viral vector) versus homologous (mRNA) COVID-19 vaccine …

Summary SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) causing COVID-
19 (coronavirus disease 2019) poses a greater health risk to immunocompromized …

Understanding adaptive immunity against SARS-CoV-2 is a major requisite for the
development of effective vaccines and treatments for COVID-19. CD4+ T cells play an …

Objectives (1) To plot the trajectory of humoral and cellular immune responses to the primary
(two‐dose) COVID‐19 mRNA series and the third/booster dose in B‐cell‐depleted multiple …

Our goal was to determine the cellular immune response (CIR) in a sample of the Borriana
COVID-19 cohort (Spain) to identify associated factors and their relationship with infection …

Introduction: Although the adaptive immune responses to the CoronaVac vaccine are
known, their dynamics in indigenous communities remain unclear. In this study, we …

A previously unknown coronavirus, named Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2), emerged in the city of Wuhan, China, in December 2019. Its …

We highlighted in this current paper similar prolonged respiratory presentation with COVID-
19 pneumonia in four severely immunocompromised patients currently being treated with …